<?xml version="1.0" encoding="UTF-8"?>
<XML><RECORDS>
<RECORD>
	<REFERENCE_TYPE>31</REFERENCE_TYPE>
	<AUTHORS>
		<AUTHOR>Caviness, John N</AUTHOR>
		<AUTHOR>Driver-Dunckley, Erika</AUTHOR>
		<AUTHOR>Connor, Donald J</AUTHOR>
		<AUTHOR>Sabbagh, Marwan N</AUTHOR>
		<AUTHOR>Hentz, Joseph G</AUTHOR>
		<AUTHOR>Noble, Brie</AUTHOR>
		<AUTHOR>Evidente, Virgilio Gerald H</AUTHOR>
		<AUTHOR>Shill, Holly A</AUTHOR>
		<AUTHOR>Adler, Charles H</AUTHOR>
	</AUTHORS>
	<YEAR>2007</YEAR>
	<TITLE>Defining mild cognitive impairment in Parkinson's disease.</TITLE>
	<SECONDARY_TITLE>Movement disorders : official journal of the Movement Disorder Society</SECONDARY_TITLE>
	<VOLUME>22</VOLUME>
	<NUMBER>9</NUMBER>
	<PAGES>1272-7</PAGES>
	<DATE>2007 Jul 15</DATE>
	<ALTERNATE_TITLE>Mov. Disord.</ALTERNATE_TITLE>
	<CUSTOM1>http://www.ncbi.nlm.nih.gov/pubmed/17415797?dopt=Abstract</CUSTOM1>
	<ABSTRACT>Our purpose was to characterize a state of mild cognitive impairment (MCI) in Parkinson's disease (PD) (PD-MCI) that would be analogous to the MCI that is posited as a precursor of Alzheimer's disease (AD). We categorized 86 PD subjects in a brain bank population as either cognitively normal (PD-CogNL), PD-MCI using criteria that included a 1.5 standard deviation or greater deficit upon neuropsychological testing consistently across at least one cognitive domain without dementia, and PD dementia (PD-D) using DSM-IV criteria. Twenty-one percent of our PD sample met criteria for PD-MCI, 62% were PD-CogNL, and 17% had PD-D. The mean duration of PD and MMSE scores of the PD-MCI group were intermediate and significantly different from both PD-CogNL and PD-D. The cognitive domain most frequently abnormal in PD-MCI was frontal/executive dysfunction followed by amnestic deficit. Single domain PD-MCI was more common than PD-MCI involving multiple domains. We conclude that a stage of clinical cognitive impairment in PD exists between PD-CogNL and PD-D, and it may be defined by applying criteria similar to the MCI that is posited as a precursor of AD. Defining PD-MCI offers an opportunity for further study of cognitive impairment in PD and targets for earlier therapeutic intervention.</ABSTRACT>
</RECORD>
</RECORDS></XML>